Animal Models for the Evaluation of Theranostic Radiopharmaceuticals

Basit Öğe Kaydı
dc.authoridSoyluoglu, Selin/0000-0003-4473-7138
dc.contributor.authorSoyluoglu, Selin
dc.contributor.authorDurmus-Altun, Gulay
dc.date.accessioned2024-06-12T11:12:43Z
dc.date.available2024-06-12T11:12:43Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Theranostic is a new field of medicine that combines diagnosis and patient-specific targeted treatment. In the theranostic approach, it is aimed to detect diseased cells by using targeted molecules using disease-specific biological pathways and then destroy them by cellular irradiation without damaging other tissues. Diagnostic tests guide the use of specific therapeutic agents by demonstrating the presence of the receptor/molecule on the target tissue. As the therapeutic agent is administered to patients who have a positive diagnostic test, the efficacy of treatment in these patients is largely guaranteed. As therapeutic efficacy can be predicted by therapeutic agents, it is also possible to monitor the response to treatment. Many diagnostic and therapeutic procedures in nuclear medicine are classified as theranostic. I-131 treatment and scintigraphy are the best exam- ples of the theranostic application. Likewise, Lu-177 / Y-90 octreotate for neuroendocrine tumors, Lu-177 PSMA for metastatic or treatment-resistant prostate cancer, Y-90 SIRT for metastatic liver cancer, and Ra-223 for bone metastasis of prostate cancer are widely used. Moreover, nanopartides are one of the most rapidly developing subjects of theranostics. Diagnostic and therapeutic agents that show fluorescent, ultrasonic, magnetic, radioactive, contrast, pharmacological drug or antibody properties are loaded into the nanoparticle to provide theranostic use. Methods: This article reviewed general aspects of preclinical models for theranostic research, and presented examples from the literature. Conclusion: To achieve successful results in rapidly accelerating personalized treatment research of today, the first step is to conduct appropriate preclinical studies.en_US
dc.identifier.doi10.2174/1874471013666200425223428
dc.identifier.endpage22en_US
dc.identifier.issn1874-4710
dc.identifier.issn1874-4729
dc.identifier.issue1en_US
dc.identifier.pmid32334507en_US
dc.identifier.scopus2-s2.0-85103994420en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage15en_US
dc.identifier.urihttps://doi.org/10.2174/1874471013666200425223428
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23282
dc.identifier.volume14en_US
dc.identifier.wosWOS:000641557600004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPreclinical Modelsen_US
dc.subjectTumor Modelsen_US
dc.subjectAnimal Studyen_US
dc.subjectTheranosticsen_US
dc.subjectPharmacological Drugen_US
dc.subjectLung Canceren_US
dc.titleAnimal Models for the Evaluation of Theranostic Radiopharmaceuticalsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu